Why Tempus AI Inc. (TEM) Soared Last Week

We precocious published a database of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to instrumentality a look astatine wherever Tempus AI Inc. (NASDAQ:TEM) stands against different firms that recorded double-digit gains past week.

Ten companies finished the past trading week connected a precocious note, outperforming the 3 large indices with double-digit gains amid a flurry of catalysts, including upcoming net releases, that sparked buying appetite.

Week-on-week, the Nasdaq rallied by 6.7 percent, the S&P 500 clocked successful a 4.59-percent gain, portion the Dow Jones was up by 2.48 percent.

In this article, we person listed past week’s apical 10 performing stocks and elaborate the reasons down their gains. The stocks were chosen based connected the highest percent summation successful closing prices connected April 25 arsenic against their prices connected April 17, oregon the week prior.

To travel up with the list, we considered lone the companies with a $2-billion marketplace capitalization and a $5-million trading volume.

Copyright: nexusplexus / 123RF Stock Photo

Tempus AI Inc. (NASDAQ:TEM)

Telehealth institution Tempus AI saw its stock prices surge by 30.78 percent week-on-week to decorativeness astatine $52.90 connected Friday versus the $40.45 registered connected April 17 arsenic investors repositioned portfolios up of its upcoming net merchandise portion cheering its recently inked concern with AstraZeneca and Pathos AI.

According to the company, it is scheduled to merchandise the results of its archetypal 4th operational and fiscal highlights connected Tuesday, May 6, 2025.

In different news, Tempus AI Inc. (NASDAQ:TEM) clinched a caller $200-million woody with AstraZeneca and Pathos AI for the improvement of a multimodal instauration exemplary successful oncology. The full magnitude includes information licensing and exemplary improvement fees.

The model, which volition utilize TEM’s de-identified oncology data, volition beryllium utilized to stitchery biologic and objective insights, observe caller cause targets, and make therapeutics for the broader oncology community.

Upon completion, the exemplary volition beryllium shared among each 3 parties to beforehand their idiosyncratic efforts to amended diligent care.

“Generative AI and the emergence of ample multimodal models is the last catalyst needed to usher successful precision medicine successful oncology astatine scale,” said TEM CEO Eric Lefkofsky.

“Tempus has spent the past decennary investing billions of dollars into collecting the indispensable information needed for a instauration exemplary of this benignant to instrumentality shape. We look guardant to moving with AstraZeneca and Pathos to use AI-enabled solutions to beforehand therapies successful an effort to assistance patients unrecorded longer and healthier lives,” helium added.